

Investment objective

Aims to achieve a long-term total return (before fees and expenses) that exceeds the MSCI World ex Australia Index, in \$A hedged with net dividends reinvested (**Benchmark**).

The Fund invests in the Walter Scott Global Equity Fund, which will not invest in 'tobacco' securities as defined by the Global Industry Classification Standard or 'controversial weapons' securities as defined by MSCI, Inc.

Key information

Fund details	
APIR code	MAQ0557AU
mFund code	MPS06
Inception date	20 March 2008
Underlying Fund investment manager	Walter Scott & Partners Limited (Edinburgh, UK)
Fund size	\$995.2m
Distribution frequency	Annually
Management fee*	1.28% pa
Minimum investment (Direct)	\$5,000
Unit prices and spreads	macquarie.com.au/unit_prices

*Read the Product Disclosure Statement for more details on fees and costs.

Fund performance to 31 August 2021

	Total Fund return (gross)	Total Fund return (net)	Benchmark return	Total excess return (net)
1 month (%)	2.56	2.45	2.69	-0.24
3 months (%)	9.55	9.21	7.01	2.20
1 year (%)	31.22	29.58	29.38	0.20
3 years (% pa)	16.54	15.07	13.37	1.70
5 years (% pa)	17.16	15.69	14.37	1.32
7 years (% pa)	14.60	13.16	11.88	1.28
Since inception (% pa)	12.66	11.24	10.18	1.06

Past performance is not a reliable indicator of future performance.

Total returns are calculated based on changes in net asset values and assumes the reinvestment of distributions.

Total net Fund returns are quoted after the deduction of fees and expenses. Due to individual circumstances, your net returns may differ from the net returns quoted above.

Top 10 stocks


Stock	Sector	Industry	Holding (%)
Microsoft Corp	Information technology	Software	3.94
Keyence Corp	Information technology	Electronic Equipment Instruments & Components	3.48
Alphabet Inc	Communication services	Interactive Media & Services	3.39
Taiwan Semiconductor Manufacturing	Information technology	Semiconductors & Semiconductor Equipment	3.14
Adobe Inc	Information technology	Software	2.92
Edwards Lifesciences Corp	Health care	Health Care Equipment & Supplies	2.79
Nike Inc	Consumer discretionary	Textiles Apparel & Luxury Goods	2.61
Mastercard Inc	Information technology	IT Services	2.60
Novo Nordisk A/S	Health care	Pharmaceuticals	2.55
Intuitive Surgical Inc	Health care	Health Care Equipment & Supplies	2.53
Total number of stocks			49

Walter Scott Global Equity Fund (Hedged)

Macquarie Professional Series

Monthly report – 31 August 2021

Growth of \$100,000 since inception




Past performance is not a reliable indicator of future performance.

Sector weights

Sector	Fund (%)	Benchmark (%)
Information technology	34.76	23.24
Health care	18.46	12.83
Consumer discretionary	12.41	11.81
Industrials	11.05	10.52
Consumer staples	8.82	6.94
Communication services	5.39	9.42
Materials	4.26	4.02
Financials	2.37	12.97
Utilities	0.61	2.80
Energy	0.00	2.78
Real estate	0.00	2.65
Cash	1.87	0.00
Total	100	100


Sector attribution (12 months to date)



Region weights

Region	Fund (%)	Benchmark (%)
North America	59.23	72.62
Europe ex UK	18.70	15.15
Japan	8.50	6.77
United Kingdom	4.72	4.20
Asia ex Japan	3.84	1.27
Emerging Markets	3.14	0.00
Cash	1.87	0.00
Total	100	100

Region attribution (12 months to date)



Walter Scott Global Equity Fund (Hedged)

Macquarie Professional Series

Monthly report – 31 August 2021

Performance summary

- The Fund returned 2.45% in August 2021, compared with a return for the Benchmark of 2.69%, with renewed challenges to the market's long-dominant recovery narrative unable to prevent global equity markets making further gains.
- With the exception of the Energy sector, all market sectors again moved higher in August. The largest relative contributors to the Fund's performance were holdings in Health Care, including Novo Nordisk and Waters Corporation, and an underweight to Energy. These were partially offset by an underweight to Financials. There were no initial purchases or final sales within the portfolio during the month.
- The unfortunate emergence of diabetes and obesity as global epidemics makes Novo Nordisk's pioneering work with insulin and related treatments ever more valuable to healthcare systems around the world. The big story of an excellent set of H1 results was the spectacular rollout of the company's new obesity drug, Wegovy. Approved by the US Food & Drug Administration in early June, Wegovy was launched into the US market the following week. Just five weeks later, it had generated as many prescriptions as Saxenda, Novo's previous obesity drug, had managed in four years. Perhaps this shouldn't have been a surprise; clinical trials that showed high levels of sustained weight loss in people with Type 2 diabetes had created considerable excitement among patients and doctors alike. While this initial surge in demand for Wegovy will inevitably moderate, over the long term the market opportunity is huge. In the US, some 70% of the population is overweight or obese, although only a fraction receive treatment. However, awareness of the condition and its human and economic consequences is growing, and with it demand for effective therapies. Keen to encourage healthier lifestyles, many employers have been quick to add Wegovy to employee insurance plans. Outside the US, approval is expected in the EU later this year and given the region's high engagement with Saxenda expectations are high.
- Second-guessing the direction of markets is not part of Walter Scott's analytical mandate. What can appear a fool's errand at the best of times seems to offer even less chance of success today. Eschewing crystal-ball gazing, Walter Scott retains a disciplined focus on the underlying fundamentals of the Fund's portfolio companies, ensuring that they remain capable of delivering sustainable growth over the long term irrespective of inevitable macroeconomic and market vagaries.

For more information speak to your financial adviser, call us on 1800 814 523, email mim.clientservice@macquarie.com or visit macquarie.com

Important information

Weights and attribution breakdown for sector, stocks and region relates to the underlying fund, and are sourced from Macquarie and Factset.

Macquarie Investment Management Australia Limited ABN 55 092 552 611 AFS Licence 238321 is the issuer of units in, and responsible entity of the Fund.

The information in this report is provided for general information purposes only and is not, and should not be construed as, an advertisement, an invitation, an offer, a solicitation of an offer or a recommendation to participate in any investment strategy or take any other action, including to buy or sell any product offered by any member of the Macquarie Group. The above information is not personal advice and does not take into account the investment objectives, financial situation or needs of any person. Investors should consider the offer document of the Fund in deciding whether to acquire or continue to hold units in the Fund. The offer document is available by contacting us on 1800 814 523. Past performance is not a reliable indicator of future performance.

Future results are impossible to predict. In preparing this document, reliance may have been placed, without independent verification, on the accuracy and completeness of information available from external sources. This report may also include opinions, estimates and other forward-looking statements which are, by their very nature, subject to various risks and uncertainties. Actual events or results may differ materially, positively or negatively, from those reflected or contemplated in such forward-looking statements. Forward-looking statements constitute the investment manager's judgement as at the date of preparation of this report and are subject to change without notice. To the maximum extent permitted by law, no member of the Macquarie Group nor its directors, employees or agents accept any liability for any loss arising from the use of this document, its contents or otherwise arising in connection with it.

Other than Macquarie Bank Limited (MBL), none of the entities noted in this document are authorised deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia). The obligations of these entities do not represent deposits or other liabilities of MBL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of these entities, unless noted otherwise.